Jay Mohr

Jay Muhr serves as Chief Operating & Business Officer and Head of Commercial Development at AZTherapies. He also is a Co-Founder and serves as Advisor at Locust Walk Partners. He is also an Angel Investor. He brings over 20 years of experience in the biopharmaceutical industry. His expertise encompasses leadership roles in entrepreneurial ventures, as well as P&L, commercial/marketing and business development in large pharma and small biopharma organizations. He brings therapeutic area expertise in a wide range of indications. As founding CEO, Jay secured a license from Fujisawa (now Astellas) for Gloucester Pharmaceuticals' lead compound, Istodax (romidepsin), a novel HDAC inhibitor. He was instrumental in raising over $30 million in initial venture capital financing from blue chip venture capitalists. Istodax was recently approved by the FDA for use in hematologic cancers, which, in turn, led to Gloucester's acquisition by Celgene for $640 million. During his tenure as President and CBO, Jay played a key role in the sale/merger of Variagenics to Hyseq (subsequently Nuvelo and Arca Biopharma) resulting in a 6x return for shareholders. Jay has also served in executive positions at Zelos Therapeutics, Serono (now EMD Serono) and Schering-Plough (now Merck). Jay holds an MBA in Health Care Management and Marketing from The Wharton School and a BA in Economics from Vanderbilt University. Jay is the immediate past President and a 7-year Board member of the Wharton Health Care Management Alumni Association, and immediate past Chair of the Health Care Alumni Conference. Jay also serves as Co-Chair of the Parents' Fund at Notre Dame Academy. He continues to serve as a mentor at MassBio's MassConnect program for life science entrepreneurs.